OncoMatch/Clinical Trials/NCT06555744
A Study of ZW191 in Participants With Solid Tumors
Is NCT06555744 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ZW191 for advanced solid tumors.
Treatment: ZW191 — The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: antibody-drug conjugate
Exception: Topoisomerase I inhibitor (TOPO1i) antibody drug conjugate
Has received prior Topoisomerase I inhibitor(TOPO1i) antibody drug conjugate treatment, regardless of washout period.
Lab requirements
Blood counts
Other adequate organ function.
Kidney function
Other adequate organ function.
Liver function
Other adequate organ function.
Cardiac function
Cardiac left ventricular function, as defined by left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram (ECHO) or multigated acquisition scan (MUGA).
Adequate cardiac function: Cardiac left ventricular function, as defined by left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram (ECHO) or multigated acquisition scan (MUGA). Other adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Yale University · New Haven, Connecticut
- The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · Columbus, Ohio
- Stephenson Cancer Center · Oklahoma City, Oklahoma
- NEXT Oncology · San Antonio, Texas
- NEXT Virginia · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify